The Financial Services Commission has approved about 220 billion won in National Growth Fund support for projects by GC Biopharma in Cheongju and Hana Micron in Asan. The decision was made at the fund’s investment review meeting on October 29, with the two companies pursuing different projects in biotechnology and system semiconductors.
Two projects target different strategic industries
GC Biopharma will spend 210 billion won on US clinical research and development and production facilities for a subcutaneous immune globulin treatment. The company plans to finance 170 billion won through a loan from the Advanced Strategic Industries Fund and provide the remaining 40 billion won itself. The treatment is used for immune deficiencies and autoimmune diseases and is administered into the fatty layer beneath the skin rather than through a vein.
- GC Biopharma project
- 210 billion won for US clinical research and production facilities
- Hana Micron project
- 70 billion won for an Asan system semiconductor testing plant
- Fund financing
- 220 billion won combined across the two projects
Hana Micron will invest 70 billion won to build a system semiconductor testing plant in Asan. The project includes 50 billion won in fund financing and 20 billion won from the company. The plant is expected to test the performance and quality of mobile application processors for on-device artificial intelligence, including Samsung Electronics’ Exynos 2700.
The commission said GC Biopharma’s project could support entry into the global blood-product market while contributing to jobs and industry-academic cooperation in the Cheongju area. It said Hana Micron’s facility could strengthen domestic semiconductor back-end processing and supply-chain capabilities. The same review also approved 140 billion won for Yongin semiconductor equipment maker PSK and 100 billion won for a 400-megawatt solar project in Haenam, but those approvals are separate from the 220 billion won allocated to the two companies in this story.
